HIV gp120 plus specific peptides are recognized in a similar manner to specific HLA plus peptide by HLA-restricted antigen-specific T-cell lines.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

HIV gp120 plus specific peptides are recognized in a similar manner to specific HLA plus peptide by HLA-restricted antigen-specific T-cell lines.

Viral Immunol. 2000;13(1):9-17. Unique Identifier : AIDSLINE MED/20195302
Sheikh J; Souberbielle B; Westby M; Austen B; Dalgleish AG; Division of Surgery, St. George's Hospital Medical School,; Tooting, London, UK.

Abstract: HIV induces disease only following chronic activation of the immune system. Other retroviruses such as the mouse mammary tumour virus (MMTV) activate a large percentage of T cells by encoding a superantigen (SAg). To date there is no evidence that HIV encodes a SAg. An alternative way to induce pan-activation of the immune system is by allogeneic stimulation, which occurs following transplantation. Here we extend previous work which demonstrated that HIVpg120 could bind peptides in a similar manner to HLA, by demonstrating that human antigen presenting cells (APCs) expressing gp120 (but not DR1) can present a DR1-restricted peptide to induce proliferation of a DR1-restricted peptide-specific T-cell line in a similar manner to the same peptide presented by a DR1 expressing APC. Our data provide strong support for the hypothesis that the HLA-like regions of gp120 encode functional properties shared with HLA, and could explain the extraordinary clinical and immunological similarities between AIDS and chronic graft versus host disease.

Keywords: JOURNAL ARTICLE Animal Antigen Presentation Antigen-Presenting Cells/IMMUNOLOGY Cell Line Human HIV Antibodies/IMMUNOLOGY HIV Envelope Protein gp120/*IMMUNOLOGY/METABOLISM HLA Antigens/*IMMUNOLOGY/METABOLISM HLA-DR1 Antigen/IMMUNOLOGY/METABOLISM Lymphocyte Transformation Mice Peptide Fragments/IMMUNOLOGY Peptides/*IMMUNOLOGY/METABOLISM Support, Non-U.S. Gov't T-Lymphocytes/*IMMUNOLOGY

000830
A0081015

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .